ALX Oncology to Announce Phase 2 Trial Results for HER2-Positive Gastric Cancer at 4:30 PM EDT
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology Holdings Inc. (NASDAQ:ALXO) will announce Phase 2 trial results for evorpacept in treating advanced HER2-positive gastric cancer at 4:30 PM EDT today. The company will host an investor conference call and webcast to share the topline data results.
July 31, 2024 | 9:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ALX Oncology Holdings Inc. will announce Phase 2 trial results for evorpacept in treating advanced HER2-positive gastric cancer. The results could significantly impact the company's stock price depending on the data's success.
The announcement of Phase 2 trial results is a critical event for biotech companies. Positive results could lead to a significant increase in stock price due to potential future revenues from successful drug development. Conversely, negative results could lead to a decline in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100